VIOXX Drug Patent Profile
✉ Email this page to a colleague
When do Vioxx patents expire, and when can generic versions of Vioxx launch?
Vioxx is a drug marketed by Merck and is included in two NDAs.
The generic ingredient in VIOXX is rofecoxib. There are two drug master file entries for this compound. Additional details are available on the rofecoxib profile page.
Summary for VIOXX
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 115 |
Patent Applications: | 3,337 |
Formulation / Manufacturing: | see details |
DailyMed Link: | VIOXX at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for VIOXX
US Patents and Regulatory Information for VIOXX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Merck | VIOXX | rofecoxib | SUSPENSION;ORAL | 021052-001 | May 20, 1999 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Merck | VIOXX | rofecoxib | TABLET;ORAL | 021042-002 | May 20, 1999 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Merck | VIOXX | rofecoxib | SUSPENSION;ORAL | 021052-002 | May 20, 1999 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Merck | VIOXX | rofecoxib | TABLET;ORAL | 021042-001 | May 20, 1999 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Merck | VIOXX | rofecoxib | TABLET;ORAL | 021042-003 | Feb 25, 2000 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VIOXX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Merck | VIOXX | rofecoxib | SUSPENSION;ORAL | 021052-001 | May 20, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Merck | VIOXX | rofecoxib | SUSPENSION;ORAL | 021052-001 | May 20, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Merck | VIOXX | rofecoxib | TABLET;ORAL | 021042-003 | Feb 25, 2000 | ⤷ Try a Trial | ⤷ Try a Trial |
Merck | VIOXX | rofecoxib | SUSPENSION;ORAL | 021052-002 | May 20, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Merck | VIOXX | rofecoxib | TABLET;ORAL | 021042-003 | Feb 25, 2000 | ⤷ Try a Trial | ⤷ Try a Trial |
Merck | VIOXX | rofecoxib | SUSPENSION;ORAL | 021052-001 | May 20, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VIOXX
See the table below for patents covering VIOXX around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Algeria | 2200 | Compositions pour un traitement une fois par jour des maladies ayant pour mediateur la 2-cyclooxygenase. | ⤷ Try a Trial |
Australia | 691119 | ⤷ Try a Trial | |
Czech Republic | 288175 | Phenyl heterocyclic derivatives, process of their preparation and pharmaceutical preparations in which they are comprised | ⤷ Try a Trial |
New Zealand | 332670 | Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases comprising 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone | ⤷ Try a Trial |
Yugoslavia | 40394 | ⤷ Try a Trial | |
Finland | 20012510 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |